Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,188,784
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.80
  • Price/Sales 4.48
  • Price/Cash Flow 11.56
  • Price/Book 5.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.14
  • Number of Estimates 6
  • High Estimate 1.18
  • Low Estimate 1.11
  • Prior Year 1.11
  • Growth Rate Est. (year over year) +2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.01 +7.18%
on 07/20/18
66.99 -0.79%
on 08/08/18
+3.57 (+5.68%)
since 07/13/18
3-Month
57.49 +15.60%
on 05/18/18
66.99 -0.79%
on 08/08/18
+6.78 (+11.36%)
since 05/14/18
52-Week
52.83 +25.80%
on 04/03/18
66.99 -0.79%
on 08/08/18
+3.79 (+6.05%)
since 08/14/17

Most Recent Stories

More News
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.

AZN : 38.98 (-0.10%)
MRK : 66.46 (-0.39%)
INCY : 66.45 (+2.44%)
AMGN : 195.76 (+0.08%)
IHI Joining Efforts to Improve Outcomes, Reduce Disparities in Maternal Care

Having a baby can be a healthy and joyful experience, but each year, an estimated 750 women die in the United States as a result of complications of childbirth, and more than 50,000 suffer...

MRK : 66.46 (-0.39%)
Global Scientific Instrument Market 2018-2023 - Key Players are Agilent, Bruker, Danaher, Horiba, Thermo Fisher, Waters, Roche, Pelkin Elmer and Merck

The "Scientific Instrument Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.

MRK : 66.46 (-0.39%)
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More

Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More

CVS : 71.38 (+2.71%)
AMTD : 58.50 (+1.23%)
MRK : 66.46 (-0.39%)
CME : 166.31 (+1.44%)
MFC : 18.74 (+2.85%)
PSA : 215.93 (+0.34%)
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

AGEN : 1.79 (+2.29%)
MRK : 66.46 (-0.39%)
INCY : 66.45 (+2.44%)
GILD : 77.31 (+0.18%)
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance

Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.

ENDP : 16.10 (+5.99%)
MRK : 66.46 (-0.39%)
VRTX : 175.93 (+0.50%)
SGEN : 74.63 (+1.12%)
Recommended Cash Offer for Vernalis plc

LNSTY : 14.3500 (-0.42%)
MRK : 66.46 (-0.39%)
BK : 50.97 (+1.66%)
BAX : 70.71 (unch)
NVS : 82.14 (-0.36%)
VNLPF : 0.2190 (unch)
AMGN : 195.76 (+0.08%)
BIIB : 343.63 (+0.83%)
Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down

Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.

MRK : 66.46 (-0.39%)
VRTX : 175.93 (+0.50%)
SGEN : 74.63 (+1.12%)
PRGO : 69.45 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 67.25
1st Resistance Point 66.85
Last Price 66.46
1st Support Level 66.16
2nd Support Level 65.86

See More

52-Week High 66.99
Last Price 66.46
Fibonacci 61.8% 61.58
Fibonacci 50% 59.91
Fibonacci 38.2% 58.24
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar